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CASE

REPORT

Drug-induced dermatomyositis after
lacosamide: A case report
Rebecca G. Gaffney, BA,a,b,c Meera Tarazi, BA,a,b,d and Victoria P. Werth, MDa,b
Philadelphia, Pennsylvania and New Brunswick, New Jersey
Key words: dermatomyositis; drug induced; lacosamide.

INTRODUCTION
Dermatomyositis (DM) is an autoimmune connective tissue disease characterized by cutaneous
manifestations, muscle inflammation, and proximal
muscle weakness. DM may develop in patients after
an environmental insult initiates an autoimmune
reaction in genetically predisposed individuals.1
Environmental triggers of DM cited in the literature
include ultraviolet radiation, viruses, vaccines,
medical devices, emotional stress, and drugs.2
Although the role of drug-induced DM is not
well established, many drugs have been implicated
in the development of DM. A review of 70 case
reports by Seidler and Gottlieb3 identified hydroxyurea, penicillamine, and hydroxymethylglutaryl
Co-A reductase inhibitors as the most common
drugs described in drug-induced DM. Other
drugs included phenylbutazone, cyclophosphamide, etoposide, imatinib mesylate, interferon-a2b,
omeprazole, phenytoin, tegafur, alfuzosin, etanercept, and gemfibrozil.3 Here we describe a case
of a woman who had DM after treatment with
lacosamide. To our knowledge, drug-induced DM
from lacosamide has not been reported previously.

CASE
A 49-year-old white woman with a history of
partial seizures presented to her dermatologist with a
3-month history of rash and proximal muscle
weakness in February 2017. The patient had a red,
pruritic rash on her chest 1 month after starting
150 mg of lacosamide twice daily for her seizures.
The rash traveled to her bilateral ears, elbows, hands,
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and the nasal bridge over the next 2 months with
mild transient proximal muscle weakness during this
time. Clinical evaluation found antinuclear
antibodies (1:160) with speckled pattern. Serum
studies for Smith, RNP, SS-A/Ro, SS-B/La, Mi-2, and
Jo-1 were negative. Additionally, creatinine kinase
and aldolase were within normal limits. Antithyroid
peroxidase antibodies were significantly elevated at
305 IU/mL (normal level, \35 IU/mL); however,
thyroid function test results were within normal
limits. A biopsy of the proximal interphalangeal joint
found a lichenoid dermatitis with positive granular
C5B-9 and weaker IgM and C3 deposition along the
basement membrane zone on direct immunofluorescence. She was prescribed topical steroids and
referred to a private rheumatology practice for
further assessment. The patient was given a
preliminary diagnosis of autoimmune thyroiditis
and DM by her rheumatologist in March 2017 and
was prescribed 10 mg/d of prednisone with a 5-mg
taper each month. She completed her prednisone
taper before presenting to our clinic in May 2017.
On presentation, the patient reported minimally
improved skin symptoms since taking prednisone.
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The remainder of review of systems was negative.
Physical examination was significant for erythema
on the chest, elbows, right ear, extensor upper arms,
and erythematous plaques or Gottron papules over
the proximal interphalangeal joints. There were
proximal fingernail fold telangiectasias on
dermoscopy. She had 5/5 muscle strength in both
upper and lower extremities. She was prescribed
400 mg/d of hydroxychloroquine (HCQ) and
continued with topical steroids.
On follow-up examination 3 months later, the
patient’s skin findings were unchanged from those of
her previous visit, and she had a documented
Cutaneous Dermatomyositis Disease Area and
Severity Index (CDASI) score of 13. Despite her
limited improvement, the patient was kept on the
same dose of HCQ but was instructed to stop taking
lacosamide by her neurologist. Four months after
discontinuing lacosamide, the patient presented to
our clinic with significant improvement of her skin
eruption. On examination, the patient’s CDASI score
decreased 7 points from her last visit to a score of 6.
Her pulmonary function test results were within
normal limits, and pelvic ultrasound scan found a
benign fibroid. Given the improvement of her
symptoms after withdrawal of lacosamide, the
patient was kept on the same dose of HCQ.

DISCUSSION
Biopsy-proven DM developed in our patient
1 month after starting lacosamide and had persistent
symptoms despite treatment with prednisone and
3 months of maximum-dose HCQ. After being off of
lacosamide for 4 months, her CDASI improved 7
points from a score of 13 to a score of 6, a decrease
that is defined as significant clinical improvement
based on CDASI validation studies.4 These findings
fulfill the World Health Organization causality
assessment criteria for a ‘‘probable causal relationship’’ between lacosamide and the development of
DM.5 Although the patient did not have concurrent
lung disease or malignancy based on screening tests,
she will still require routine monitoring.
Given the known association of autoimmune
thyroiditis with DM, the patient was likely genetically
predisposed to DM development, and lacosamide
may have acted as an environmental trigger.6

Lacosamide, a third-generation antiepileptic drug
(AED), acts on neuronal voltage-gated sodium
channels and has only been previously described
to cause cutaneous manifestations through
hypersensitivity reactions.7 The mechanism for
drug-induced DM remains unclear; however, it has
been proposed that certain drugs may inflict damage
to endothelial cells leading to release of cellular
antigens and epitope spreading, which causes an
autoimmune reaction.2 Though early generations of
AEDs have actually been found to dampen the
immune response, lacosamide is a newer drug and
its effects on nonneuronal cells and the immune
system have not been studied.8

CONCLUSION
Although lacosamide has not been reported
previously to induce dermatomyositis, we have
found a temporal relationship in the development
of dermatomyositis with lacosamide exposure and
improvement of symptoms upon withdrawal of the
drug. Physicians should be aware of this relationship
and consider lacosamide as a possible etiologic
factor in development of dermatomyositis.
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